EE141 Cost-Effectiveness of TP53 and IGHV Biomarker Testing Prior to First-Line Treatment With Novel Agents for Chronic Lymphocytic Leukemia
Dec 1, 2022, 00:00
10.1016/j.jval.2022.09.393
https://www.valueinhealthjournal.com/article/S1098-3015(22)02597-9/fulltext
Title :
EE141 Cost-Effectiveness of TP53 and IGHV Biomarker Testing Prior to First-Line Treatment With Novel Agents for Chronic Lymphocytic Leukemia
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)02597-9&doi=10.1016/j.jval.2022.09.393
First page :
Section Title :
Open access? :
No
Section Order :
12202